Abstract: Regulation of enzymatic activity is vital to living organisms. Here, we report the development and the genetic optimization of an artificial zymogen requiring the action of a natural protease to upregulate its latent asymmetric transfer hydrogenase activity.
spatially and temporally control the activity of toxic enzymes that are expressed as pro-enzymes, also called zymogens. The unraveling of their catalytic activity requires the selective hydrolysis by a cognate protease to convert them into their corresponding active state.
In recent years, artificial metalloenzymes (ArMs hereafter), which result from anchoring an organometallic catalyst within a macromolecular scaffold, have emerged as an attractive alternative to organometallic catalysts. Thanks to their genetic encoding, well defined second coordination sphere, and nonnatural organometallic cofactor, these hybrid catalysts combine attractive features of both homogeneous catalysts and enzymes. [4] [5] [6] [7] [8] Our group recently demonstrated that such ArMs improve the bio-compatibility of the organometallic cofactor, the protein host providing protection against deactivation, allowing their integration into cascades with natural enzymes. [10] [11] [12] In a biomimetic spirit, we surmised that the activity of an anchored catalyst precursor might be upregulated by the action of an external trigger, ideally a natural enzyme, at a remote position in the host protein. Such systems could form the basis of more elaborate cross-regulated enzyme cascades whereby the product of the ArM-catalyzed reaction inhibits the activating enzyme.
Herein, we report the optimization of an artificial zymogen based on the biotin-streptavidin technology (Figure 1 ). B) The biotinylated cofactor is activated upon coordination of a tripeptide that is released from the C-terminus of an engineered streptavidin (Sav = streptavidin, only one monomer depicted for clarity; AA = aminoacid).
Inspired by a publication by Whitesides, we and others exploit the biotin-streptavidin technology for the creation of ArMs. [13] [14] [15] [16] [17] [18] In the context of upregulation, we hypothesized that a biotinylated Cp*M moiety (M = Rh (III), Ir(III)) might prove versatile as: (i) The [Cp* biot MCl2]2 precursor (or in combination with wild-type streptavidin, WT Sav hereafter) shows limited catalytic activity, both for C-H activation (M = Rh(III)) and for imine reduction (M = Rh(III) or Ir(III)). [19] [20] [21] (ii) Addition of a suitable ligand (e.g.
amidoamines, derived from natural amino acids) leads to significant rate acceleration for the transfer hydrogenation of imines and ketones. [19] [20] [21] [22] (iii) Embedding a Cp*Ir moiety within Sav shields the cofactor from inhibition by other proteins, enabling enzyme cascades. [10] [11] [12] In the context of ligand-accelerated catalysis, [23] [19] The tripeptide is thought to coordinate in a bidentate fashion to the iridium via the nitrogen atoms of the first two residues (i.e. a primary amine and an amide). [19, 22] Selected results, collected in Table 1 , lead to the following conclusions: i) In the absence of the tripeptide, the biotinylated cofactor displays limited catalytic activity, both in the absence and in the presence of Sav (Table 1, entries 1, 2) . ii) Addition of glycineamide or a di-or tripeptide leads to significant ATHase activity (Table S1 , SI), confirming their ligand-accelerating effect on the ArMs. [19, 20, 22] iii) Although the activity of all peptide-iridium complexes [ Figure S2 , SI), TONs > 3500 can be achieved with ketone 2 within 48 hours using 300 mM substrate, highlighting the robustness of the ArM. v) Next, Sav mutants were screened in the presence of SGF. As previously observed, [20, 26] Having identified suitable combinations of Sav variants and tripeptides, the genetic encoding of Sav variants that include a protease cleavage site flanked by the tripeptide ligand was undertaken: Factor Xa was selected as the activating protease. [27] Correspondingly, its recognition site (e.g. IDGR\)
followed by the XGF-activating peptide (X = S, Y) was genetically encoded at the C-terminus of Sav, starting at position A156. The C-terminal sequence of the mature Sav (A156-V-Q-Q159) [28] was replaced by I156-D-G-R\S-G-F162 and I156-D-G-R\Y-G-F162, for both K121A Sav (abbreviated K121A--SGF) and K121E Sav (K121E--YGF). UPLC-MS analysis revealed that both K121A--SGF and K121E--YGF are cleaved within a few hours by Factor Xa ( Figure S1, SI) (Table 2 , entries 3 and 4). Together, these results suggest that the presence of the activating tripeptides at the C-terminus of Sav have no effect in the absence of Factor Xa, and the protease itself does not activate the cofactor by direct complexation. ii) Incubation with Factor Xa restores the ATHase activity and enantioselectivity of both zymogens ( Figure S1 , SI).
In conclusion, an artificial zymogen with latent ATHase activity was designed and its upregulation by a natural enzyme demonstrated. Various creative strategies have been pursued in the past to engineer switchable homogeneous catalysts. [21, 29, 30] To the best of our knowledge, however, this constitutes the first report of an artificial zymogen upregulated by a natural protease. Both the host protein and the activating peptide ligand can be genetically encoded and orthogonally optimized to improve the catalytic activity and fine-tune enantioselectivity. This proof of concept presents a biocompatible strategy for the upregulation of an ArM, paving the way to implement and regulate bioorthogonal catalytic activity within a living organism.
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